BGMS - Bio Green Med Solution Book Valuation of Business

The price trend visualization for Bio Green Med Solution Inc (BGMS) demonstrates the dynamics of an asset whose strategy relies on scaling a portfolio of kinase inhibitors to combat solid tumors through alliances with major industry players. The indicator reaches 0.01. The business is based on patents that allow for the targeted inhibition of malignant cell replication, while Bio Green Med Solution Inc (BGMS) functions as a scientific hub, outsourcing formula synthesis and clinical trials to external contractors.

cyclacel.com (BGMS) - Company Book Value from 09/13/2025 to 10/28/2026

Comprehensive metric breakdowns and analytics for Bio Green Med Solution (BGMS)

- price and consensus price forecast:

Stock Quotes Cyclacel|BGMS - Price Target Chart

- market capitalization data:

Market Capitalization Bio Green Med Solution Inc.|BGMS - Total Company Value

- book capitalization data:

Net Asset Value per Share Bio Green Med Solution|BGMS - Company Book Value|Capitalization to Book Value Ratio cyclacel.com|BGMS - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Bio Green Med Solution Inc|BGMS - Long-Term Debt to Equity|Current Liabilities to Capital Bio Green Med Solution Inc.|BGMS - Company Debts|Debt to Book Capitalization Ratio Bio Green Med Solution Inc.|BGMS - Company Long-Term Debt|Short-Term Debt Bio Green Med Solution

Initial company analysis:Cyclacel - BGMS

Flagship merchandise of Bio Green Med Solution Inc

The book value capitalization of Bio Green Med Solution Inc (BGMS) represents the volume of net assets minus all liabilities, allowing an investor to assess the real intrinsic value of the business and its protection against default. The trend in book value capitalization reflects the financial foundation of Bio Green Med Solution Inc (BGMS), ensuring stability during the development of scarce oncology drugs amid high market demand.

Key competitors